fda update on tirzepatide BREAKING NEWS!!! A weight loss drug more effective than Semaglutide has been approved by the today. (Zepbound for weight loss and Mounjaro for diabetes) showed a 15-20.9% weight change in FDA Approves Tirzepatide for Obstructive

Our studys superior histology results provide evidence for this

These factors are built into the pricing to ensure both efficiency and effectiveness in achieving your health goals

For example, in a 72-week clinical trial (61), a weekly dose of 15 mg of tirzepatide led to 21% total body weight loss compared with 3% in the placebo group receiving only a hypocaloric diet

In this regard, semaglutide is becoming increasingly important, as demonstrated in Table 3, which summarizes the previous results of phase 3 clinical trials

Another online provider, Juniper, told patients in a blog post published in December 2025: Wegovy 7.2mg now delivers weight-loss outcomes (20.7%) almost identical to Mounjaro 15mg (20.9%), making it a cost-effective alternative amid rising Mounjaro prices. Mounjaro (tirzepatide

GLP2 Mechanism of Action GLP2 exerts its therapeutic effects through a unique dual agonist mechanism, simultaneously activating both GIP and GLP-1 receptors with distinct pharmacological properties at each target